![[English (Australia)]](/fileadmin/_processed_/c/7/csm_Banner_Header_Int_News_New_head_Regenerative_Tech_1200x378px_c6f023daf1.jpg "[English (Australia)]")
In addition to the successful dental business with its biomaterials, the regeneration specialist Geistlich is also active in other areas of the body. The Regenerative Technologies (RT) business distributes Geistlich's high-quality biomaterials in sports medicine, aesthetics and reconstructive surgery.
David Wemans has been appointed Global Head of Regenerative Technologies (RT). The Economics graduate, who deepened his knowledge at INSEAD in Fontainebleau has been working for Geistlich for nearly 17 years. Known for his customer focus, he has established Geistlich's regenerative solutions with clinicians during this time. Most recently, he was deputy head of the RT business.
Under the leadership of David Wemans, Regenerative Technologies will focus even more strongly on customer needs. The focus will be on collaboration with leading scientists and clinicians, the generation of clinical data on the safety and effectiveness of regenerative materials and the practical training of specialists.
Co-developing new surgical technology
Over the past seven years, Carrie Hartill has played a key role in driving forward the Regenerative Technologies business. Born in the UK, she has enriched Geistlich with her expertise and made a major contribution to the growth of the business.
Among other things, Carrie Hartill played a key role in further progress of the AMIC® technique, a method for treating cartilage damage in the knee, ankle and hip. With this project, she has made a significant contribution to the well-being of patients worldwide. Carrie will retire at the end of 2024.
“I look forward to following Geistlich’s further progress as David Wemans develops new solutions for patients in the field of Regenerative Technologies, and I wish him every success. Furthermore, I would like to thank Carrie Hartill for her great commitment to Geistlich during her years with us, and I trust that she will enjoy a balance of relaxation and further innovation during her retirement.”, says Mark Spilker, Chief Scientific Officer of Geistlich.